These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 1498450)

  • 21. Tumor growth instability and its implications for chemotherapy.
    Castorina P; Carcò D; Guiot C; Deisboeck TS
    Cancer Res; 2009 Nov; 69(21):8507-15. PubMed ID: 19861540
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Gompertz model with delays and treatment: mathematical analysis.
    Bodnar M; Piotrowska MJ; Foryś U
    Math Biosci Eng; 2013 Jun; 10(3):551-63. PubMed ID: 23906135
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Control by Viability in a Chemotherapy Cancer Model.
    Serhani M; Essaadi H; Kassara K; Boutoulout A
    Acta Biotheor; 2019 Sep; 67(3):177-200. PubMed ID: 30949871
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Optimal chemotherapy regimens: influence of tumours on normal cells and several toxicity constraints.
    Matveev AS; Savkin AV
    IMA J Math Appl Med Biol; 2001 Mar; 18(1):25-40. PubMed ID: 11339336
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Modeling the chemotherapy-induced selection of drug-resistant traits during tumor growth.
    Cho H; Levy D
    J Theor Biol; 2018 Jan; 436():120-134. PubMed ID: 29030212
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Overview of resistance to systemic therapy in patients with breast cancer.
    Gonzalez-Angulo AM; Morales-Vasquez F; Hortobagyi GN
    Adv Exp Med Biol; 2007; 608():1-22. PubMed ID: 17993229
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Factors affecting the development of permanent drug resistance and its impact upon neoadjuvant chemotherapy.
    Coldman AJ; Goldie JH
    Recent Results Cancer Res; 1986; 103():69-78. PubMed ID: 3738197
    [No Abstract]   [Full Text] [Related]  

  • 28. Therapies with diverse mechanisms of action kill cells by a similar exponential process in advanced cancers.
    Blagoev KB; Wilkerson J; Stein WD; Yang J; Bates SE; Fojo T
    Cancer Res; 2014 Sep; 74(17):4653-62. PubMed ID: 25183789
    [TBL] [Abstract][Full Text] [Related]  

  • 29. An integrated cellular and sub-cellular model of cancer chemotherapy and therapies that target cell survival.
    Cook AB; Ziazadeh DR; Lu J; Jackson TL
    Math Biosci Eng; 2015 Dec; 12(6):1219-35. PubMed ID: 26775858
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Adjuvant chemotherapy and the kinetic refractoriness of minimal residual tumors.
    Reizenstein P; Mathé G
    Bull Soc Sci Med Grand Duche Luxemb; 1989; 126(1):57-8. PubMed ID: 2743532
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Chemotherapeutic Dose Scheduling Based on Tumor Growth Rates Provides a Case for Low-Dose Metronomic High-Entropy Therapies.
    West J; Newton PK
    Cancer Res; 2017 Dec; 77(23):6717-6728. PubMed ID: 28986381
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Voreloxin, formerly SNS-595, has potent activity against a broad panel of cancer cell lines and in vivo tumor models.
    Hoch U; Lynch J; Sato Y; Kashimoto S; Kajikawa F; Furutani Y; Silverman JA
    Cancer Chemother Pharmacol; 2009 Jun; 64(1):53-65. PubMed ID: 18931998
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Advanced targeted therapies in cancer: Drug nanocarriers, the future of chemotherapy.
    Pérez-Herrero E; Fernández-Medarde A
    Eur J Pharm Biopharm; 2015 Jun; 93():52-79. PubMed ID: 25813885
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Experimental chemotherapy and concepts related to the cell cycle.
    Tannock IF
    Int J Radiat Biol Relat Stud Phys Chem Med; 1986 Feb; 49(2):335-55. PubMed ID: 3510996
    [TBL] [Abstract][Full Text] [Related]  

  • 35. On drug resistance and metronomic chemotherapy: A mathematical modeling and optimal control approach.
    Ledzewicz U; Wang S; Schattler H; Andre N; Heng MA; Pasquier E
    Math Biosci Eng; 2017 Feb; 14(1):217-235. PubMed ID: 27879129
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Sensitivity of latent cancer to chemotherapy.
    Schrek R
    Med Hypotheses; 1992 Jul; 38(3):215-6. PubMed ID: 1513276
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Modes of resistance to antitumor agents.
    Kessel D
    In Vivo; 1994; 8(5):829-34. PubMed ID: 7727732
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Enhanced sensitivity to the HER1/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib hydrochloride in chemotherapy-resistant tumor cell lines.
    Dai Q; Ling YH; Lia M; Zou YY; Kroog G; Iwata KK; Perez-Soler R
    Clin Cancer Res; 2005 Feb; 11(4):1572-8. PubMed ID: 15746062
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Chemotherapy for tumors: an analysis of the dynamics and a study of quadratic and linear optimal controls.
    de Pillis LG; Gu W; Fister KR; Head T; Maples K; Murugan A; Neal T; Yoshida K
    Math Biosci; 2007 Sep; 209(1):292-315. PubMed ID: 17306310
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Implications of certain cell kinetic and biological parameters for preoperative chemotherapy.
    Hill BT
    Recent Results Cancer Res; 1986; 103():41-53. PubMed ID: 3526475
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.